BioArctic AB (FRA:B9A) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 04, 2026)


FRA:B9A BioArctic AB FRA:B9A
84 GF Score
Price €29.72
GF Value €41.45
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is BioArctic AB Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BioArctic AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:B9A vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, BioArctic AB's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioArctic AB Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where BioArctic AB's Margin of Safety % (DCF Earnings Based) falls into.


FRA:B9A
84GF Score
BioArctic AB FRA:B9A
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioArctic AB (FRA:B9A) Overvalued in 2026?

Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued. The current stock price of €29.72 is trading 28.3% below its estimated GF Value™ of €41.45. GuruFocus considers BioArctic AB to be Modestly Undervalued.

Key valuation signals for FRA:B9A:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €41.45 vs. price of €29.72 (28.3% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the FRA:B9A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioArctic AB Business Description

Address Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
84GF Score

Get the complete analysis for FRA:B9A

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.72
Price
€41.45
GF Value